Advertisement

Epidemiology of Infections in Cancer Patients

  • Teresa R. ZembowerEmail author
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 161)

Abstract

Although major advances in the care of cancer patients over the past several decades have resulted in improved survival, infectious complications remain a significant cause of morbidity and mortality. To successfully identify, treat, and prevent infections, a comprehensive understanding of risk factors that predispose to infection and of commonly encountered pathogens is necessary. In addition, clinicians must keep abreast of the changing epidemiology of infections in this population. As therapeutic modalities continue to evolve, as established pathogens become increasingly drug resistant, and as new pathogens are discovered, successful management of infections will continue to present challenges in the years to come.

Keywords

Epidemiology Infection Cancer Risk factors Emerging pathogens 

References

  1. 1.
    Chang HY et al (1976) Causes of death in adults with acute leukemia. Medicine 55(3):259–268 (Baltimore)PubMedGoogle Scholar
  2. 2.
    Hersh EM et al (1965) Causes of death in acute leukemia: a ten-year study of 414 patients from 1954–1963. JAMA 193:105–109PubMedGoogle Scholar
  3. 3.
    Homsi J et al (2000) Infectious complications of advanced cancer. Support Care Cancer 8(6):487–492PubMedGoogle Scholar
  4. 4.
    Hughes WT (1971) Fatal infections in childhood leukemia. Am J Dis Child 122(4):283–287PubMedGoogle Scholar
  5. 5.
    Inagaki J, Rodriguez V, Bodey GP (1974) Proceedings: causes of death in cancer patients. Cancer 33(2):568–573PubMedGoogle Scholar
  6. 6.
    Mayo JW, Wenzel RP (1982) Rates of hospital-acquired bloodstream infections in patients with specific malignancy. Cancer 50(1):187–190PubMedGoogle Scholar
  7. 7.
    Nosari A et al (1991) Infections in haematologic neoplasms: autopsy findings. Haematologica 76(2):135–140PubMedGoogle Scholar
  8. 8.
    Viscoli C, Castagnola E (1995) Factors predisposing cancer patients to infection. In: Klastersky K (ed) Infectious complications of cancer. Kluwer Academic, Boston, pp 1–30Google Scholar
  9. 9.
    Morittu L et al (1989) Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 59(5):801–804PubMedCentralPubMedGoogle Scholar
  10. 10.
    Freifeld AG, Kaul DR (2008) Infection in the patient with cancer, in Abeloff’s clinical oncology. In: Abeloff MD et al (eds) Churchill Livingstone, Philadelphia, pp 717–738Google Scholar
  11. 11.
    Viscoli C, Castagnola E (2009) Prophylaxis and empirical therapy of infection in cancer patients. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Doublas, and Bennett’s principle and practice of infectious diseases. Churchill Livingstone, Philadelphia, pp 3793-3808Google Scholar
  12. 12.
    Donnelly JP, Blijlevens NMA, De Pauw BE (2009) Infections in the immunocompromised host: general principles. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, pp 3781–3792Google Scholar
  13. 13.
    Vusirikala M (2009) Supportive care in hematologic malignancies, in Wintrobe’s clinical hematology. In: Greer JP et al (ed) Lippincott Williams and Wilkins, Philadelphia, pp 1747–1790Google Scholar
  14. 14.
    Maschmeyer G, Haas A (2008) The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 31(3):193–197PubMedGoogle Scholar
  15. 15.
    Todar K (2008) Immune defense against bacterial pathogens: innate immunity. In: Todar K (ed) Todar’s online textbook of bacteriologyGoogle Scholar
  16. 16.
    Todar K (2008) Immune defense against bacterial pathogens: adaptive or acquired immunity. In Todar K (ed) Todar’s online textbook of bacteriologyGoogle Scholar
  17. 17.
    Donnelly JP (1995) Chemoprophylaxis for the prevention of bacterial and fungal infections. Cancer Treat Res 79:45–81PubMedGoogle Scholar
  18. 18.
    Roth RR, James WD (1988) Microbial ecology of the skin. Annu Rev Microbiol 42:441–464PubMedGoogle Scholar
  19. 19.
    Schroder JM (2010) The role of keratinocytes in defense against infection. Curr Opin Infect Dis 23(2):106–110PubMedGoogle Scholar
  20. 20.
    Awada A et al (1992) Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 15(1):33–48PubMedGoogle Scholar
  21. 21.
    Axelrod PI, Lorber B, Vonderheid EC (1992) Infections complicating mycosis fungoides and Sezary syndrome. JAMA 267(10):1354–1358PubMedGoogle Scholar
  22. 22.
    Glauser MP, Zinner SH (1982) Mechanisms of acquisition and development of bacterial infections in cancer patients. In: Klastersky J (ed) Infections in cancer patients. Raven Press, New York, pp 13–30Google Scholar
  23. 23.
    Hall VC et al (2003) Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 48(4):548–552PubMedGoogle Scholar
  24. 24.
    Dorman SE et al (1999) Viral infections in interferon-gamma receptor deficiency. J Pediatr 135(5):640–643PubMedGoogle Scholar
  25. 25.
    Fahey JL et al (1963) Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia. Am J Med 35:698–707PubMedGoogle Scholar
  26. 26.
    Favoreel HW et al (2003) Virus complement evasion strategies. J Gen Virol 84(Pt 1):1–15PubMedGoogle Scholar
  27. 27.
    Salmon SE (1973) Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 10(2):135–144PubMedGoogle Scholar
  28. 28.
    Sheridan JF et al (1990) Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 75(7):1583–1586PubMedGoogle Scholar
  29. 29.
    Wagner RR (1963) Cellular resistance to viral infection, with particular reference to endogenous interferon. Bacteriol Rev 27:72–86PubMedCentralPubMedGoogle Scholar
  30. 30.
    Johnston RB Jr (1988) Current concepts: immunology. Monocytes and macrophages. N Engl J Med 318(12):747–752PubMedGoogle Scholar
  31. 31.
    Barbuto S et al (2013) Induction of innate and adaptive immunity by delivery of poly dA:dT to dendritic cells. Nat Chem Biol 9(4):250–256PubMedCentralPubMedGoogle Scholar
  32. 32.
    Steinman RM, Inaba K (1988) The binding of antigen presenting cells to T lymphocytes. Adv Exp Med Biol 237:31–41PubMedGoogle Scholar
  33. 33.
    Urb M, Sheppard DC (2012) The role of mast cells in the defence against pathogens. PLoS Pathog 8(4):e1002619PubMedCentralPubMedGoogle Scholar
  34. 34.
    Hall LJ et al (2013) Natural killer cells protect against mucosal and systemic infection with the enteric pathogen Citrobacter rodentium. Infect Immun 81(2):460–469PubMedCentralPubMedGoogle Scholar
  35. 35.
    Horowitz A, Stegmann KA, Riley EM (2011) Activation of natural killer cells during microbial infections. Front Immunol 2:88PubMedCentralPubMedGoogle Scholar
  36. 36.
    Marras F, Bozzano F, De Maria A (2011) Involvement of activating NK cell receptors and their modulation in pathogen immunity. J Biomed Biotechnol 2011:152430PubMedCentralPubMedGoogle Scholar
  37. 37.
    Steinhauer EH et al (1985) Natural killer cytotoxic factor induction by K562 cells in patients with advanced cancer: correlation with production of interferon. J Natl Cancer Inst 75(6):1017–1023PubMedGoogle Scholar
  38. 38.
    Bodey GP et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328–340PubMedGoogle Scholar
  39. 39.
    Feld R, Bodey GP (1977) Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 39(3):1018–1025PubMedGoogle Scholar
  40. 40.
    Freifeld AG et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–e93PubMedGoogle Scholar
  41. 41.
    Valdez JM et al (2009) Infections in patients with aplastic anemia. Semin Hematol 46(3):269–276PubMedGoogle Scholar
  42. 42.
    Schimpff SC et al (1978) Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis 137(1):14–29PubMedGoogle Scholar
  43. 43.
    Brooks WH et al (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136(6):1631–1647PubMedCentralPubMedGoogle Scholar
  44. 44.
    Han T, Takita H (1972) Immunologic impairment in bronchogenic carcinoma: a study of lymphocyte response to phytohemagglutinin. Cancer 30(3):616–620PubMedGoogle Scholar
  45. 45.
    Krick JA, Remington JS (1976) Opportunistic invasive fungal infections in patients with leukaemia lymphoma. Clin Haematol 5(2):249–310PubMedGoogle Scholar
  46. 46.
    Lum LG (1990) Immune recovery after bone marrow transplantation. Hematol Oncol Clin North Am 4(3):659–675PubMedGoogle Scholar
  47. 47.
    Orita K et al (1976) Preoperative cell-mediated immune status of gastric cancer patients. Cancer 38(6):2343–2348PubMedGoogle Scholar
  48. 48.
    Schellhammer PF et al (1976) Immune evaluation with skin testing. A study of testicular, prostatic, and bladder neoplasms. Cancer 38(1):149–156PubMedGoogle Scholar
  49. 49.
    Seligmann M et al (1984) AIDS–an immunologic reevaluation. N Engl J Med 311(20):1286–1292PubMedGoogle Scholar
  50. 50.
    Whittaker MG, Rees K, Clark CG (1971) Reduced lymphocyte transformation in breast cancer. Lancet 1(7705):892–893PubMedGoogle Scholar
  51. 51.
    Young RC et al (1972) Delayed hypersensitivity in Hodgkin’s disease. A study of 103 untreated patients. Am J Med 52(1):63–72PubMedGoogle Scholar
  52. 52.
    Kim JH, Perfect JR (1989) Infection and cyclosporine. Rev Infect Dis 11(5):677–690PubMedGoogle Scholar
  53. 53.
    Mackall CL et al (1995) Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332(3):143–149PubMedGoogle Scholar
  54. 54.
    Mackall CL et al (1994) Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84(7):2221–2228PubMedGoogle Scholar
  55. 55.
    Bishop JF et al (1981) Infections during intensive chemotherapy for non-Hodgkin’s lymphoma. Ann Intern Med 95(5):549–555PubMedGoogle Scholar
  56. 56.
    Bookman MA, Longo DL (1986) Concomitant illness in patients treated for Hodgkin’s disease. Cancer Treat Rev 13(2):77–111PubMedGoogle Scholar
  57. 57.
    Chan JC, Hensley GT, Moskowitz LB (1984) Toxoplasmosis in the central nervous system. Ann Intern Med 100(4):615–616PubMedGoogle Scholar
  58. 58.
    Hardy I et al (1991) The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 325(22):1545–1550PubMedGoogle Scholar
  59. 59.
    Hughes WT et al (1975) Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 36(6):2004–2009PubMedGoogle Scholar
  60. 60.
    Hughes WT, Townsend TR (1981) Nosocomial infections in immunocompromised children. Am J Med 70(2):412–416PubMedGoogle Scholar
  61. 61.
    Keiser PB, Nutman TB (2004) Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 17(1):208–217PubMedCentralPubMedGoogle Scholar
  62. 62.
    Sepkowitz KA (1993) Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 17(Suppl 2):S416–S422PubMedGoogle Scholar
  63. 63.
    Sepkowitz KA et al (1992) Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 267(6):832–837PubMedGoogle Scholar
  64. 64.
    Varthalitis I, Meunier F (1993) Pneumocystis carinii pneumonia in cancer patients. Cancer Treat Rev 19(4):387–413PubMedGoogle Scholar
  65. 65.
    Hosea SW et al (1981) Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 304(5):245–450PubMedGoogle Scholar
  66. 66.
    Van Der Meer JWM (1988) Defects in host-defense mechanisms. In: Rubin RH, Young LS (eds) Clinical approach to infection in the compromised host. Plenum Medical, New York, pp 41–63Google Scholar
  67. 67.
    Gaston MH et al (1986) Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 314(25):1593–1599PubMedGoogle Scholar
  68. 68.
    Jugenburg M et al (1999) The morbidity and mortality of pediatric splenectomy: does prophylaxis make a difference? J Pediatr Surg 34(7):1064–1067PubMedGoogle Scholar
  69. 69.
    Keenan RD, Boswell T, Milligan DW (1999) Do post-splenectomy patients take prophylactic penicillin? Br J Haematol 105(2):509–510PubMedGoogle Scholar
  70. 70.
    Group, A.A.I.W. et al (2013) Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older—United States, 2013. MMWR Surveill Summ 62(1):9–19Google Scholar
  71. 71.
    Group A.C.A.I.W. et al (2013) Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years–United States. MMWR Surveill Summ 62(l):2–8Google Scholar
  72. 72.
    Schimpff SC (1995) Infection in the cancer patient–diagnosis, prevention, and treatment. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Churchill Livingstone, New York, pp 2666–2675Google Scholar
  73. 73.
    Rammaert B et al (2012) Diabetes and mucormycosis: a complex interplay. Diabetes Metab 38(3):193–204PubMedGoogle Scholar
  74. 74.
    Renehan AG et al (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55(6):1619–1632PubMedGoogle Scholar
  75. 75.
    Barone BB et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300(23):2754–2764PubMedCentralPubMedGoogle Scholar
  76. 76.
    Barone BB et al (2010) Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 33(4):931–939PubMedCentralPubMedGoogle Scholar
  77. 77.
    Daly AL et al (1989) Mucormycosis: association with deferoxamine therapy. Am J Med 87(4):468–471PubMedGoogle Scholar
  78. 78.
    Pagano L et al (2004) Mucormycosis in hematologic patients. Haematologica 89(2):207–214PubMedGoogle Scholar
  79. 79.
    Balentine CJ et al (2010) Obese patients benefit from minimally invasive colorectal cancer surgery. J Surg Res 163(1):29–34PubMedGoogle Scholar
  80. 80.
    Merkow RP et al (2009) Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg 208(1):53–61PubMedGoogle Scholar
  81. 81.
    Tsujinaka S et al (2008) Visceral obesity predicts surgical outcomes after laparoscopic colectomy for sigmoid colon cancer. Dis Colon Rectum 51(12):1757–1765; discussion 1765–1767Google Scholar
  82. 82.
    Safdar A, Bodey G, Armstrong D (2011) Infections in patients with cancer: overview. In: S. A (ed) Principles and practice of cancer infectious diseases. Springer, New York, pp 3–16Google Scholar
  83. 83.
    Anand A, Glatt AE (1993) Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 17(1):109–113PubMedGoogle Scholar
  84. 84.
    Blot E et al (2003) Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 53(3):187–192PubMedGoogle Scholar
  85. 85.
    Chopra T, Alangaden GJ, Chandrasekar P (2010) Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 8(10):1113–1119PubMedGoogle Scholar
  86. 86.
    Palmore TN et al (2005) Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 26(8):680–684PubMedGoogle Scholar
  87. 87.
    Raza S et al (2010) Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov 5(1):1–9PubMedGoogle Scholar
  88. 88.
    Resnik E, Lefevre CA (1999) Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Int J Gynecol Cancer 9(6):512–514PubMedGoogle Scholar
  89. 89.
    Stewart DB, Yacoub E, Zhu J (2012) Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients. J Gastrointest Surg 16(8):1566–1572PubMedGoogle Scholar
  90. 90.
    National Cancer Institute (2009) Nutrition in cancer care (PDQ) health professional version. 30 Dec 2009. Available from http://www.cancer.gov/cancertopics/pdq/supportivecare/nutrition/HealthProfessional/page1. Last accessed 18 Aug 2013
  91. 91.
    Marin Caro MM, Laviano A, Pichard C (2007) Impact of nutrition on quality of life during cancer. Curr Opin Clin Nutr Metab Care 10(4):480–487PubMedGoogle Scholar
  92. 92.
    Pressoir M et al (2010) Prevalence, risk factors and clinical implications of malnutrition in French comprehensive cancer centres. Br J Cancer 102(6):966–971PubMedCentralPubMedGoogle Scholar
  93. 93.
    Wong PW, Enriquez A, Barrera R (2001) Nutritional support in critically ill patients with cancer. Crit Care Clin 17(3):743–767PubMedGoogle Scholar
  94. 94.
    Horie H et al (2006) Favorable effects of preoperative enteral immunonutrition on a surgical site infection in patients with colorectal cancer without malnutrition. Surg Today 36(12):1063–1068PubMedGoogle Scholar
  95. 95.
    Heyland DK et al (2001) Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 286(8):944–953PubMedGoogle Scholar
  96. 96.
    Celik JB et al (2009) The role of immunonutrition in gynecologic oncologic surgery. Eur J Gynaecol Oncol 30(4):418–421PubMedGoogle Scholar
  97. 97.
    Weisdorf SA et al (1987) Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 43(6):833–838PubMedGoogle Scholar
  98. 98.
    Irwin J, Livnat S (1987) Behavioral influences on the immune system: stress and conditioning. Prog Neuropsychopharmacol Biol Psychiatry 11(2–3):137–143PubMedGoogle Scholar
  99. 99.
    Marsland AL et al (2002) Stress, immune reactivity and susceptibility to infectious disease. Physiol Behav 77(4–5):711–716PubMedGoogle Scholar
  100. 100.
    Falagas ME et al (2010) Psychosocial factors and susceptibility to or outcome of acute respiratory tract infections. Int J Tuberc Lung Dis 14(2):141–148PubMedGoogle Scholar
  101. 101.
    Kemeny ME, Schedlowski M (2007) Understanding the interaction between psychosocial stress and immune-related diseases: a stepwise progression. Brain Behav Immun 21(8):1009–1018PubMedGoogle Scholar
  102. 102.
    Aubert A (2008) Psychosocial stress, emotions and cytokine-related disorders. Recent Pat Inflamm Allergy Drug Discov 2(2):139–148PubMedGoogle Scholar
  103. 103.
    Reiche EM, Nunes SO, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5(10):617–625PubMedGoogle Scholar
  104. 104.
    Paun BC et al (2010) Postoperative complications following surgery for rectal cancer. Ann Surg 251(5):807–818PubMedGoogle Scholar
  105. 105.
    Wilson BD, Surgalla MJ, Yates JW (1974) Aerobic and anaerobic surgical wound contamination in patients with cancer. Surg Gynecol Obstet 139(3):329–332PubMedGoogle Scholar
  106. 106.
    Morris CD et al (2003) Prospective identification of risk factors for wound infection after lower extremity oncologic surgery. Ann Surg Oncol 10(7):778–782PubMedGoogle Scholar
  107. 107.
    Gongaware RD, Slanetz CA Jr (1973) Hartmann procedure for carcinoma of the sigmoid and rectum. Ann Surg 178(1):28–30PubMedCentralPubMedGoogle Scholar
  108. 108.
    Naito H et al (1973) High incidence of acute postoperative meningitis and septicemia in patients undergoing craniotomy with ventriculoatrial shunt. Surg Gynecol Obstet 137(5):810–812PubMedGoogle Scholar
  109. 109.
    Geelhoed GW, Ketcham AS (1973) Pseudomonas meningitis complicating radical resection for radiorecurrent cancer of the paranasal sinuses: report of two patients successfully treated with intrathecal polymyxin. J Surg Oncol 5(4):365–374PubMedGoogle Scholar
  110. 110.
    Lefebvre D et al (2000) Incidence and surgical wound infection risk factors in breast cancer surgery. Presse Med 29(35):1927–1932PubMedGoogle Scholar
  111. 111.
    Vilar-Compte D et al (2004) Surgical site infections in breast surgery: case-control study. World J Surg 28(3):242–246PubMedGoogle Scholar
  112. 112.
    Accolla RS (2006) Host defense mechanisms against pathogens. Surg Infect 7(Suppl 2):S5–S7 (Larchmt)Google Scholar
  113. 113.
    Nakamura T et al (2009) Retrospective, matched case-control study comparing the oncologic outcomes between laparoscopic surgery and open surgery in patients with right-sided colon cancer. Surg Today 39(12):1040–1045PubMedGoogle Scholar
  114. 114.
    Villar HV et al (1987) Role of surgical treatment in the management of complications of the gastrointestinal tract in patients with leukemia. Surg Gynecol Obstet 165(3):217–222PubMedGoogle Scholar
  115. 115.
    Wade DS, Nava HR, Douglass HO Jr (1992) Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 69(1):17–23PubMedGoogle Scholar
  116. 116.
    Ullery BW et al (2009) Neutropenic enterocolitis. Surg Infect 10(3):307–314 (Larchmt)Google Scholar
  117. 117.
    Say CC, Donegan W (1974) A biostatistical evaluation of complications from mastectomy. Surg Gynecol Obstet 138(3):370–376PubMedGoogle Scholar
  118. 118.
    Smith MG et al (1972) Cell-mediated immune responses in chronic liver diseases. Br Med J 1(5799):527–530PubMedCentralPubMedGoogle Scholar
  119. 119.
    Lowell DM, LiVolsi VA, Ludwig ME (1983) Genital condyloma virus infection following pelvic radiation therapy: report of seven cases. Int J Gynecol Pathol 2(3):294–302PubMedGoogle Scholar
  120. 120.
    Caloglu M et al (2007) An ambiguous phenomenon of radiation and drugs: recall reactions. Onkologie 30(4):209–214PubMedGoogle Scholar
  121. 121.
    Camidge R, Price A (2001) Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 59(3):237–245PubMedGoogle Scholar
  122. 122.
    Greco FA et al (1976) Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 85(3):294–298PubMedGoogle Scholar
  123. 123.
    Smith KJ, Germain M, Skelton H (2002) Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 6(6):535–540PubMedGoogle Scholar
  124. 124.
    Spirig C et al (2009) Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report. J Med Case Rep 3:93PubMedCentralPubMedGoogle Scholar
  125. 125.
    Viscoli C, Van der Auwera P, Meunier F (1988) Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother 21(lC):149–56Google Scholar
  126. 126.
    Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58(3):317–324PubMedGoogle Scholar
  127. 127.
    Cersosimo RJ (2003) Monoclonal antibodies in the treatment of cancer. Part 1 Am J Health Syst Pharm 60(15):1531–1548Google Scholar
  128. 128.
    Reang P, Gupta M, Kohli K (2006) Biological response modifiers in cancer. Med Gen Med 8(4):33Google Scholar
  129. 129.
    Worth LL, Jeha SS, Kleinerman ES (2001), Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am 15(4):723–740, 9Google Scholar
  130. 130.
    Zhang T, Herlyn D (2009) Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother 58(4):475–492PubMedCentralPubMedGoogle Scholar
  131. 131.
    Ponce R (2008) Adverse consequences of immunostimulation. J Immunotoxicol 5(1):33–41PubMedGoogle Scholar
  132. 132.
    Rafailidis PI et al (2007) Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 109(11):2182–2189PubMedGoogle Scholar
  133. 133.
    Aksoy S et al (2009) Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 50(3):357–365PubMedGoogle Scholar
  134. 134.
    Schwartz RN, Stover L, Dutcher J (2002) Managing toxicities of high-dose interleukin-2. Oncology 16(11(13)):11–20 (Williston Park)PubMedGoogle Scholar
  135. 135.
    van der Waaij D, Berghuis JM (1974) Determination of the colonization resistance of the digestive tract of individual mice. J Hyg (Lond) 72(3):379–387Google Scholar
  136. 136.
    Johanson WG, Pierce AK, Sanford JP (1969) Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli. N Engl J Med 281(21):1137–1140PubMedGoogle Scholar
  137. 137.
    Kelly CP, Pothoulakis C, LaMont JT (1994) Clostridium difficile colitis. N Engl J Med 330(4):257–262PubMedGoogle Scholar
  138. 138.
    Gaskins HR et al (2008) Impact of the intestinal microbiota on the development of mucosal defense. Clin Infect Dis 46(2): S80–S86; discussion S144–S151Google Scholar
  139. 139.
    Lampe JW (2008) The Human Microbiome Project: getting to the guts of the matter in cancer epidemiology. Cancer Epidemiol Biomarkers Prev 17(10):2523–2524PubMedGoogle Scholar
  140. 140.
    Mans JJ et al (2009) The degree of microbiome complexity influences the epithelial response to infection. BMC Genom 10:380Google Scholar
  141. 141.
    Rabizadeh S, Sears C (2008) New horizons for the infectious diseases specialist: how gut microflora promote health and disease. Curr Infect Dis Rep 10(2):92–98PubMedCentralPubMedGoogle Scholar
  142. 142.
    Tancrede C (1992) Role of human microflora in health and disease. Eur J Clin Microbiol Infect Dis 11(11):1012–1015PubMedGoogle Scholar
  143. 143.
    Raum E et al (2008) Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany. Clin Microbiol Infect 14(1):41–48PubMedGoogle Scholar
  144. 144.
    van Vliet MJ et al (2009) Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis 49(2):262–270PubMedGoogle Scholar
  145. 145.
    Wade JC, Schimpff SC (1988) Epidemiology and prevention of infection in the compromised host. In: Rubin RH, Young LS (eds) Clinical approach to infection in the compromised host. Plenum Medical, New York, pp 5–40Google Scholar
  146. 146.
    Aisner J et al (1976) Torulopsis glabrata infections in patients with cancer. Increasing incidence and relationship to colonization. Am J Med 61(1):23–28PubMedGoogle Scholar
  147. 147.
    Boken DJ, Swindells S, Rinaldi MG (1993) Fluconazole-resistant Candida albicans. Clin Infect Dis 17(6):1018–1021PubMedGoogle Scholar
  148. 148.
    Fan-Havard P et al (1991) Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 35(11):2302–2305PubMedCentralPubMedGoogle Scholar
  149. 149.
    Meunier F, Aoun M, Bitar N (1992) Candidemia in immunocompromised patients. Clin Infect Dis 14(Suppl 1):S120–S125PubMedGoogle Scholar
  150. 150.
    Merz WG et al (1986) Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 24(4):581–584PubMedCentralPubMedGoogle Scholar
  151. 151.
    Wingard JR et al (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325(18):1274–1277PubMedGoogle Scholar
  152. 152.
    Groeger JS et al (1993) Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 119(12):1168–1174PubMedGoogle Scholar
  153. 153.
    Al Wohoush I, Chaftari AM, Raad I (2011) Catheter-related infections in cancer patients. In: Safdar A (ed) Principles and practice of cancer infectious diseases. Springer, New York, pp 113–122Google Scholar
  154. 154.
    Beekmann SE, Henderson DK (2010) Infections caused by percutaneous intravascular devices. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Doublas, and Bennett’s principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, pp 3697–3716Google Scholar
  155. 155.
    Segreti J et al (2009) Consensus conference on prevention of central line-associated bloodstream infections. J Infus Nurs 34(2):126–133Google Scholar
  156. 156.
    Schiffer CA et al (2013) Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(10):1357–1370PubMedGoogle Scholar
  157. 157.
    O’Grady NP et al (2011) Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 52(9):e162–e193PubMedCentralPubMedGoogle Scholar
  158. 158.
    Tenney JH et al (1986) Adherent microorganisms on lumenal surfaces of long-term intravenous catheters. Importance of Staphylococcus epidermidis in patients with cancer. Arch Intern Med 146(10):1949–1954PubMedGoogle Scholar
  159. 159.
    Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328(18):1323–1332PubMedGoogle Scholar
  160. 160.
    Joo EJ et al (2011) Clinical outcome of catheter salvage in neutropenic cancer patients with catheter-related infection. Scand J Infect Dis 43(4):258–263PubMedGoogle Scholar
  161. 161.
    Mermel LA et al (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 49(1):1–45PubMedGoogle Scholar
  162. 162.
    Schimpff SC et al (1972) Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 77(5):707–714PubMedGoogle Scholar
  163. 163.
    Schwartz SN et al (1978) Sources of gram-negative bacilli colonizing the tracheae of intubated patients. J Infect Dis 138(2):227–331PubMedGoogle Scholar
  164. 164.
    Allain JP et al (2009) Transfusion-transmitted infectious diseases. Biologicals 37(2):71–77PubMedGoogle Scholar
  165. 165.
    Alter HJ, Stramer SL, Dodd RY (2007) Emerging infectious diseases that threaten the blood supply. Semin Hematol 44(1):32–41PubMedGoogle Scholar
  166. 166.
    Rachoin JS et al (2009) Microbiology, time course and clinical characteristics of infection in critically ill patients receiving packed red blood cell transfusion. Vox Sang 97(4):294–302PubMedGoogle Scholar
  167. 167.
    Gottesdiener KM (1989) Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med 110(12):1001–1016PubMedGoogle Scholar
  168. 168.
    Barbara JA, Contreras M (1990) ABC of transfusion. Infectious complications of blood transfusion: viruses. BMJ 300(6722):450–453PubMedCentralPubMedGoogle Scholar
  169. 169.
    Nichols WG et al (2003) Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 101(10):4195–4200PubMedGoogle Scholar
  170. 170.
    Alter HJ et al (1989) Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321(22):1494–1500PubMedGoogle Scholar
  171. 171.
    Mayer KH, Opal SM (1989) Unusual nosocomial pathogens. Infect Dis Clin North Am 3(4):883–899PubMedGoogle Scholar
  172. 172.
    Sayers MH et al (1992) Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 116(1):55–62PubMedGoogle Scholar
  173. 173.
    Soulier JP (1984) Diseases transmissible by blood transfusion. Vox Sang 47(1):1–6PubMedGoogle Scholar
  174. 174.
    Wittner M et al (1982) Successful chemotherapy of transfusion babesiosis. Ann Intern Med 96(5):601–604PubMedGoogle Scholar
  175. 175.
    Tabor E, Gerety RJ (1984) Five cases of Pseudomonas sepsis transmitted by blood transfusions. Lancet 1(8391):1403PubMedGoogle Scholar
  176. 176.
    Wright DC et al (1985) Fatal Yersinia enterocolitica sepsis after blood transfusion. Arch Pathol Lab Med 109(11):1040–1042PubMedGoogle Scholar
  177. 177.
    Yomtovian R et al (1993) A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 33(11):902–909PubMedGoogle Scholar
  178. 178.
    Rolston KV (2009) Risk assessment and the management of neutropenic fever. In: Yeung SJ, Escalante CP, Gagel RF (eds) Medical care of cancer patients. People’s Medical Publishing House, Shelton, pp 133–138Google Scholar
  179. 179.
    Bodey GP et al (1978) Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 41(4):1610–1622PubMedGoogle Scholar
  180. 180.
    Gupta A et al (2010) Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Med Oncol 27(4):1037–1045PubMedGoogle Scholar
  181. 181.
    Jagarlamudi R et al (2000) Infections in acute leukemia: an analysis of 240 febrile episodes. Med Oncol 17(2):111–116PubMedGoogle Scholar
  182. 182.
    Menichetti F (2010) Infectious complications in neutropenic cancer patients. Intern Emerg Med 5(Suppl 1):S21–S25PubMedGoogle Scholar
  183. 183.
    Rolston KV (2005) Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40(Suppl 4):S246–S252PubMedGoogle Scholar
  184. 184.
    Schimpff SC (1977) Therapy of infection in patients with granulocytopenia. Med Clin North Am 61(5):1101–1118PubMedGoogle Scholar
  185. 185.
    Karp JE et al (1986) Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 81(2):237–242PubMedGoogle Scholar
  186. 186.
    Winston DJ et al (1983) Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med 143(1):32–36PubMedGoogle Scholar
  187. 187.
    Arning M et al (1990) Septicemia due to Streptococcus mitis in neutropenic patients with acute leukemia. Blut 61(6):364–368PubMedGoogle Scholar
  188. 188.
    Neu HC (1992) The crisis in antibiotic resistance. Science 257(5073):1064–1073PubMedGoogle Scholar
  189. 189.
    Sanders JW, Powe NR, Moore RD (1991) Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 164(5):907–916PubMedGoogle Scholar
  190. 190.
    Anaissie E (1992) Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 14(Suppl 1):S43–S53PubMedGoogle Scholar
  191. 191.
    DeGregorio MW et al (1982) Fungal infections in patients with acute leukemia. Am J Med 73(4):543–548PubMedGoogle Scholar
  192. 192.
    Fisher BD et al (1981) Invasive aspergillosis. Progress in early diagnosis and treatment. Am J Med 71(4):571–577PubMedGoogle Scholar
  193. 193.
    Gerson SL et al (1984) Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100(3):345–351PubMedGoogle Scholar
  194. 194.
    Lecciones JA et al (1992) Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 14(4):875–883PubMedGoogle Scholar
  195. 195.
    Meunier-Carpentier F, Kiehn TE, Armstrong D (1981) Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med 71(3):363–370PubMedGoogle Scholar
  196. 196.
    Ben-Ami R et al (2009) A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect 59(2):134–138PubMedGoogle Scholar
  197. 197.
    Eggimann P, Pittet D (2001) Candidiasis among non-neutropenic patients: from colonization to infection. Ann Fr Anesth Reanim 20(4):382–388PubMedGoogle Scholar
  198. 198.
    Shaukat A et al (2005) Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 159(2):181–188PubMedGoogle Scholar
  199. 199.
    Bodey G et al (1992) Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 11(2):99–109PubMedGoogle Scholar
  200. 200.
    Corey L, Spear PG (1986) Infections with herpes simplex viruses (2). N Engl J Med 314(12):749–757PubMedGoogle Scholar
  201. 201.
    Corey L, Spear PG (1986) Infections with herpes simplex viruses (1). N Engl J Med 314(11):686–691PubMedGoogle Scholar
  202. 202.
    Kaplan LJ et al (1992) Severe measles in immunocompromised patients. JAMA 267(9):1237–1241PubMedGoogle Scholar
  203. 203.
    Meyers JD, Flournoy N, Thomas ED (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153(3):478–488PubMedGoogle Scholar
  204. 204.
    Rand KH, Kramer B, Johnson AC (1982) Cancer chemotherapy associated symptomatic stomatitis: role of Herpes simplex virus (HSV). Cancer 50(7):1262–1265PubMedGoogle Scholar
  205. 205.
    Straus SE et al (1988) NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 108(2):221–237PubMedGoogle Scholar
  206. 206.
    Zahradnik JM, Spencer MJ, Porter DD (1980) Adenovirus infection in the immunocompromised patient. Am J Med 68(5):725–732PubMedGoogle Scholar
  207. 207.
    Toussaint E et al (2006) Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer 14(7):763–769PubMedGoogle Scholar
  208. 208.
    Velasco E et al (2000) Epidemiology of bloodstream infections at a cancer center. Sao Paulo Med J 118(5):131–138PubMedGoogle Scholar
  209. 209.
    Schimpff SC et al (1975) Infections in 92 splenectomized patients with Hodgkin’s disease. A clinical review. Am J Med 59(5):695–701PubMedGoogle Scholar
  210. 210.
    Fassas AB et al (2001) Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 112(1):237–241PubMedGoogle Scholar
  211. 211.
    Tsiodras S et al (2000) Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 75(10):1039–1054PubMedGoogle Scholar
  212. 212.
    Wadhwa PD, Morrison VA (2006) Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33(2):240–249PubMedGoogle Scholar
  213. 213.
    Morrison VA (1998) The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25(1):98–106PubMedGoogle Scholar
  214. 214.
    Morrison VA (2009) Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 9(5):365–370PubMedGoogle Scholar
  215. 215.
    D’Souza A et al (2010) Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 10(1):E1–E9PubMedGoogle Scholar
  216. 216.
    Jacobson DR, Zolla-Pazner S (1986) Immunosuppression and infection in multiple myeloma. Semin Oncol 13(3):282–290PubMedGoogle Scholar
  217. 217.
    Miller MI, Hoppmann RA, Pisko EJ (1987) Multiple myeloma presenting with primary meningococcal arthritis. Am J Med 82(6):1257–1258PubMedGoogle Scholar
  218. 218.
    Wachter E et al (1985) Neisseria meningitidis serogroup 29E (Z′) septicemia in a patient with far advanced multiple myeloma (plasma cell leukemia). J Clin Microbiol 21(3):464–466PubMedCentralPubMedGoogle Scholar
  219. 219.
    Paradisi F, Corti G, Cinelli R (2001) Infections in multiple myeloma. Infect Dis Clin North Am 15(2):373–384, 7–8Google Scholar
  220. 220.
    Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49(8):1211–1225PubMedGoogle Scholar
  221. 221.
    Damaj G et al (2009) Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol 83(3):246–250PubMedGoogle Scholar
  222. 222.
    Audeh YM et al (2003) Hairy cell leukemia with concurrent cryptococcus infection. Am J Hematol 72(3):223–224PubMedGoogle Scholar
  223. 223.
    Goyal R et al (1995) Hairy cell leukemia–an unusual presentation. Leuk Res 19(7):485–487PubMedGoogle Scholar
  224. 224.
    Mackowiak PA et al (1980) Infections of hairy cell leukemia. Clinical evidence of a pronounced defect in cell-mediated immunity. Am J Med 68(5):718–724PubMedGoogle Scholar
  225. 225.
    Savoie L, Johnston JB (2001) Hairy cell leukemia. Curr Treat Options Oncol 2(3):217–224PubMedGoogle Scholar
  226. 226.
    Bennett C, Vardiman J, Golomb H (1986) Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 80(5):891–896PubMedGoogle Scholar
  227. 227.
    Huang WT et al (2007) Clinical features and complications of viridans streptococci bloodstream infection in pediatric hemato-oncology patients. J Microbiol Immunol Infect 40(4):349–354PubMedGoogle Scholar
  228. 228.
    Elting LS, Bodey GP, Keefe BH (1992) Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 14(6):1201–1207PubMedGoogle Scholar
  229. 229.
    Han XY, Kamana M, Rolston KV (2006) Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol 44(1):160–165PubMedCentralPubMedGoogle Scholar
  230. 230.
    Harvey RL, Sunstrum JC (1991) Rhodococcus equi infection in patients with and without human immunodeficiency virus infection. Rev Infect Dis 13(1):139–145PubMedGoogle Scholar
  231. 231.
    Al Akhrass F et al (2012) Rhodococcus bacteremia in cancer patients is mostly catheter related and associated with biofilm formation. PLoS One 7(3):e32945PubMedCentralPubMedGoogle Scholar
  232. 232.
    Khardori N et al (1990) Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 12(6):997–1003PubMedGoogle Scholar
  233. 233.
    Yeshurun M et al (2010) Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection 38(3):211–215PubMedGoogle Scholar
  234. 234.
    Mann T et al (2010) An outbreak of Burkholderia cenocepacia bacteremia in immunocompromised oncology patients. Infection 38(3):187–194PubMedGoogle Scholar
  235. 235.
    Petrucca A et al (2004) Burkholderia cenocepacia vaginal infection in patient with smoldering myeloma and chronic hepatitis C. Emerg Infect Dis 10(11):1957–1959PubMedCentralPubMedGoogle Scholar
  236. 236.
    Aisenberg G, Rolston KV, Safdar A (2004) Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989–2003). Cancer 101(9):2134–2140PubMedGoogle Scholar
  237. 237.
    Chiu SK, Chang FY (2009) Pyomyositis caused by extended-spectrum beta-lactamase-producing Escherichia coli in a patient with acute myeloid leukemia. Int J Infect Dis 13(3):e85–e87PubMedGoogle Scholar
  238. 238.
    Sharma U, Schwan WR, Agger WA (2011) Escherichia coli pyomyositis in an immunocompromised host. WMJ 110(4):182–184PubMedGoogle Scholar
  239. 239.
    Vigil KJ et al (2010) Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis 50(3):374–380PubMedGoogle Scholar
  240. 240.
    Pfaller M, Wenzel R (1992) Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 11(4):287–291PubMedGoogle Scholar
  241. 241.
    Walsh TJ et al (1991) Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 13(3):496–503PubMedGoogle Scholar
  242. 242.
    Wingard JR, Merz WG, Saral R (1979) Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med 91(4):539–543PubMedGoogle Scholar
  243. 243.
    Sipsas NV et al (2009) Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115(20):4745–4752PubMedGoogle Scholar
  244. 244.
    Hachem R et al (2008) The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112(11):2493–2499PubMedGoogle Scholar
  245. 245.
    Dahiya MC et al (2003) Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 57(1):79–83PubMedGoogle Scholar
  246. 246.
    Lalla RV et al (2010) A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18(8):985–992PubMedCentralPubMedGoogle Scholar
  247. 247.
    Redding SW et al (2004) Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97(1):47–52PubMedGoogle Scholar
  248. 248.
    Schelenz S et al (2011) Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. J Oral Pathol Med 40(1):83–89PubMedGoogle Scholar
  249. 249.
    Anaissie E, Bodey GP (1989) Nosocomial fungal infections. Old problems and new challenges. Infect Dis Clin North Am 3(4):867–882PubMedGoogle Scholar
  250. 250.
    Hachem RY et al (2004) Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101(7):1594–1600PubMedGoogle Scholar
  251. 251.
    Miceli MH, Diaz JA, Lee SA (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11(2):142–151PubMedGoogle Scholar
  252. 252.
    Pfaller MA et al (2009) Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 47(1):117–123PubMedCentralPubMedGoogle Scholar
  253. 253.
    Kalter DC et al (1986) Genital white piedra: epidemiology, microbiology, and therapy. J Am Acad Dermatol 14(6):982–993PubMedGoogle Scholar
  254. 254.
    Nahass GT et al (1993) Disseminated infection with Trichosporon beigelii. Report of a case and review of the cutaneous and histologic manifestations. Arch Dermatol 129(8):1020–1023PubMedGoogle Scholar
  255. 255.
    Walsh TJ et al (1986) Trichosporonosis in patients with neoplastic disease. Medicine 65(4):268–279 (Baltimore)PubMedGoogle Scholar
  256. 256.
    Pagano L et al (2011) Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 66(Suppl 1):i5–14PubMedGoogle Scholar
  257. 257.
    Campo M, Lewis RE, Kontoyiannis DP (2010) Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect 60(5):331–337PubMedGoogle Scholar
  258. 258.
    Gamis AS et al (1991) Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis 13(6):1077–1088PubMedGoogle Scholar
  259. 259.
    Lortholary O et al (2010) International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 54(10):4446–4450PubMedCentralPubMedGoogle Scholar
  260. 260.
    Nucci M et al (1992) Three cases of infection with Fusarium species in neutropenic patients. Eur J Clin Microbiol Infect Dis 11(12):1160–1162PubMedGoogle Scholar
  261. 261.
    Enache-Angoulvant A, Hennequin C (2005) Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 41(11):1559–1568PubMedGoogle Scholar
  262. 262.
    Ben-Ami R et al (2009) Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 48(8):1033–1041PubMedGoogle Scholar
  263. 263.
    Chaturvedi V, Chaturvedi S (2011) Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol 19(11):564–571PubMedCentralPubMedGoogle Scholar
  264. 264.
    MacDougall L et al (2011) Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg Infect Dis 17(2):193–199PubMedCentralPubMedGoogle Scholar
  265. 265.
    Perfect JR et al (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50(3):291–322PubMedGoogle Scholar
  266. 266.
    Kumar D, Humar A (2010) Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am 24(2):395–412PubMedGoogle Scholar
  267. 267.
    Kaltsas A, Sepkowitz K (2012) Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. Curr Opin Infect Dis 25(4):423–430PubMedGoogle Scholar
  268. 268.
    Torres HA, Davila M (2012) Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 9(3):156–166PubMedGoogle Scholar
  269. 269.
    Roberts RR et al (2009) Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 49(8):1175–1184PubMedGoogle Scholar
  270. 270.
    Kamboj M et al (2010) The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 16(11):1576–1581PubMedCentralPubMedGoogle Scholar
  271. 271.
    Vydra J et al (2012) Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55(6):764–770PubMedCentralPubMedGoogle Scholar
  272. 272.
    Ghanem G et al (2007) Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 28(9):1054–1059PubMedGoogle Scholar
  273. 273.
    Wudhikarn K, Gingrich RD, de Magalhaes M (2013) Silverman, Daptomycin nonsusceptible enterococci in hematologic malignancy and hematopoietic stem cell transplant patients: an emerging threat. Ann Hematol 92(1):129–131PubMedGoogle Scholar
  274. 274.
    Morris PG et al (2008) Emergence of MRSA in positive blood cultures from patients with febrile neutropenia–a cause for concern. Support Care Cancer 16(9):1085–1088PubMedGoogle Scholar
  275. 275.
    Chemaly RF et al (2010) Characteristics and outcomes of methicillin-resistant Staphylococcus aureus surgical-site infections in patients with cancer: a case-control study. Ann Surg Oncol 17(6):1499–1506PubMedGoogle Scholar
  276. 276.
    Reish RG et al (2013) Infection following implant-based reconstruction in 1952 consecutive breast reconstructions: salvage rates and predictors of success. Plast Reconstr Surg 131(6):1223–1230PubMedGoogle Scholar
  277. 277.
    Rogers SN et al (2008) Which patients are most at risk of methicillin resistant Staphylococcus aureus: a review of admissions to a regional maxillofacial ward between 2001 and 2005. Br J Oral Maxillofac Surg 46(6):439–444PubMedGoogle Scholar
  278. 278.
    Shiomori T et al (2007) Clinical features of head and neck cancer patients with methicillin-resistant Staphylococcus aureus. Acta Otolaryngol 127(2):180–185PubMedGoogle Scholar
  279. 279.
    Watters K, O’Dwyer TP, Rowley H (2004) Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences? J Laryngol Otol 118(9):694–699PubMedGoogle Scholar
  280. 280.
    Cattaneo C et al (2008) Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61(3):721–728PubMedGoogle Scholar
  281. 281.
    Arnan M et al (2011) Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30(3):355–360PubMedGoogle Scholar
  282. 282.
    Gudiol C et al (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65(2):333–341PubMedGoogle Scholar
  283. 283.
    Irfan S et al (2008) Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 8:80PubMedCentralPubMedGoogle Scholar
  284. 284.
    Kunz AN, Brook I (2010) Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections. Chemotherapy 56(6):492–500PubMedGoogle Scholar
  285. 285.
    Ortega M et al (2009) Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 63(3):568–574PubMedGoogle Scholar
  286. 286.
    Sood P et al (2012) Emergence of multidrug resistant acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J Indian Med Assoc 110(7):439–444PubMedGoogle Scholar
  287. 287.
    Vigil KJ et al (2009) Multidrug-resistant Escherichia coli bacteremia in cancer patients. Am J Infect Control 37(9):741–745PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Division of Infectious Disease, Feinberg School of MedicineNorthwestern UniversityChicagoUSA

Personalised recommendations